Revelation Financial Statements From 2010 to 2024

REVB Stock  USD 0.76  0.01  0.67%   
Revelation Biosciences financial statements provide useful quarterly and yearly information to potential Revelation Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Revelation Biosciences financial statements helps investors assess Revelation Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Revelation Biosciences' valuation are summarized below:
Gross Profit
90.9 M
Market Capitalization
3.2 M
Earnings Share
(17.53)
We have found one hundred seventeen available trending fundamental ratios for Revelation Biosciences, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Revelation Biosciences recent market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. As of November 28, 2024, Market Cap is expected to decline to about 3.9 M. The current year's Enterprise Value is expected to grow to about (1.8 M)

Revelation Biosciences Total Revenue

0.0

Check Revelation Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Revelation Biosciences' main balance sheet or income statement drivers, such as Interest Expense of 42.2 K, Total Revenue of 0.0 or Other Operating Expenses of 5.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.54. Revelation financial statements analysis is a perfect complement when working with Revelation Biosciences Valuation or Volatility modules.
  
Check out the analysis of Revelation Biosciences Correlation against competitors.
For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.

Revelation Biosciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets11.6 M12.2 M1.2 B
Slightly volatile
Accounts Payable812.7 K1.4 M954.8 K
Very volatile
Cash11.4 M12 M78.1 M
Slightly volatile
Long Term Debt135.7 M200.3 M136.7 M
Slightly volatile
Net ReceivablesM8.8 M6.3 M
Slightly volatile
Good Will29.3 M30.8 M27 M
Slightly volatile
Short Term Investments449.1 K472.8 K101.1 M
Slightly volatile
Total Liabilities5.3 M5.6 M1.1 B
Slightly volatile
Long Term Investments192.4 M223.2 M171.1 M
Slightly volatile
Intangible Assets3.2 M2.6 M4.1 M
Slightly volatile
Total Current Liabilities5.3 M5.6 M1.1 B
Slightly volatile
Other Liabilities32.4 M58.3 M22.1 M
Slightly volatile
Other Current Assets148 K155.8 K4.2 M
Slightly volatile
Total Current Assets11.5 M12.1 M63.9 M
Slightly volatile
Common Stock25226534.2 M
Slightly volatile
Property Plant Equipment142.2 K149.7 KM
Pretty Stable
Short and Long Term Debt24.4 M27.4 M29.9 M
Slightly volatile
Short Term Debt2.5 M2.6 M18.8 M
Slightly volatile
Other Current Liabilities2.2 M4.2 M829.1 K
Slightly volatile
Non Current Assets Total61.8 K65.1 K4.9 M
Pretty Stable
Common Stock Shares Outstanding240.1 K228.6 K39.4 K
Slightly volatile
Liabilities And Stockholders Equity12.8 M12.2 M2.5 M
Slightly volatile
Cash And Short Term Investments6.3 M12 MM
Slightly volatile
Capital Stock252265796.8 K
Pretty Stable
Short and Long Term Debt Total13.4 K15.1 K16.4 K
Slightly volatile
Current Deferred Revenue2.3 M2.6 M2.9 M
Slightly volatile

Revelation Biosciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses5.8 M8.7 M8.9 M
Slightly volatile
Total Operating Expenses13.5 M8.7 M15.8 M
Pretty Stable
Selling General Administrative4.3 M4.5 M19.1 M
Slightly volatile
Tax Provision11.2 M13.3 M9.1 M
Slightly volatile
Net Interest Income81.1 M106.8 M69.7 M
Slightly volatile
Interest Income105 M148.7 M91.1 M
Slightly volatile
Depreciation And Amortization38 K25 K14.3 K
Slightly volatile
Selling And Marketing Expenses21.4 K22.5 K112.1 K
Slightly volatile
Research Development4.5 M4.1 M1.4 M
Slightly volatile
Reconciled Depreciation24.5 K25 K18.4 K
Slightly volatile

Revelation Biosciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation23.8 K25 K730.2 K
Slightly volatile
Total Cash From Financing Activities13.3 M14 M191.2 M
Slightly volatile
End Period Cash Flow14.8 M12 M51.7 M
Slightly volatile
Stock Based Compensation267.2 K155.7 K111.8 K
Slightly volatile
Begin Period Cash FlowM5.3 M55.5 M
Slightly volatile
Issuance Of Capital Stock12.4 M14 M8.9 M
Slightly volatile
Dividends Paid6.1 M6.9 M7.5 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables556 K861.3 K539.6 K
Slightly volatile
Capex To Depreciation2.0E-42.0E-46.2907
Slightly volatile
Payables Turnover0.01750.01840.1
Slightly volatile
Cash Per Share49.9752.5952460
Slightly volatile
Days Payables Outstanding20.8 K19.8 K5.6 K
Slightly volatile
Income Quality63.6260.59088.5082
Slightly volatile
Net Debt To EBITDA13212639.8962
Slightly volatile
Current Ratio2.232.18293.2379
Slightly volatile
Graham Number17.6718.6013186
Slightly volatile
Capex Per Share0.00.011.2293
Slightly volatile
Days Of Payables Outstanding20.8 K19.8 K5.6 K
Slightly volatile
Ebt Per Ebit0.01320.01391.5486
Very volatile
Effective Tax Rate0.00350.003731.4956
Slightly volatile
Quick Ratio2.232.18293.2379
Slightly volatile
Net Income Per E B T0.80.90.9772
Slightly volatile
Cash Ratio2.12.15493.1274
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.810.910.9916
Slightly volatile

Revelation Biosciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.9 M4.1 M72.8 M
Slightly volatile

Revelation Fundamental Market Drivers

Forward Price Earnings7.7942
Cash And Short Term Investments12 M

Revelation Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
27th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Revelation Biosciences Financial Statements

Revelation Biosciences stakeholders use historical fundamental indicators, such as Revelation Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Revelation Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Revelation Biosciences' assets and liabilities are reflected in the revenues and expenses on Revelation Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Revelation Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.6 M2.3 M
Cost Of Revenue25 K18.5 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Revelation Biosciences is a strong investment it is important to analyze Revelation Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revelation Biosciences' future performance. For an informed investment choice regarding Revelation Stock, refer to the following important reports:
Check out the analysis of Revelation Biosciences Correlation against competitors.
For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. If investors know Revelation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revelation Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(17.53)
Return On Assets
(0.51)
Return On Equity
(2.70)
The market value of Revelation Biosciences is measured differently than its book value, which is the value of Revelation that is recorded on the company's balance sheet. Investors also form their own opinion of Revelation Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Revelation Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revelation Biosciences' market value can be influenced by many factors that don't directly affect Revelation Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revelation Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revelation Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revelation Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.